Examkin

Question

Difficulty: HardMonitoring and Treatment Evaluation

A 54-year-old man is evaluated in the clinic for a new-onset tremor and diffuse headaches that began 5 days ago. He underwent a deceased-donor renal transplantation 8 months ago for end-stage renal disease secondary to hypertensive nephrosclerosis. His maintenance immunosuppressive regimen consists of tacrolimus, mycophenolate mofetil, and low-dose prednisone. Two weeks ago, he was diagnosed with paroxysmal atrial fibrillation; at that time, his primary care physician initiated therapy with diltiazem and apixaban.

On physical examination, blood pressure is 142/88 mmHg and pulse is 78/min and irregularly irregular. A coarse resting tremor is observed in the bilateral upper extremities. The remainder of the examination is unremarkable.

Laboratory studies show:
Serum sodium: 139 mEq/L
Serum potassium: 5.1 mEq/L
Serum chloride: 104 mEq/L
Serum bicarbonate: 22 mEq/L
Blood urea nitrogen: 48 mg/dL
Serum creatinine: 2.6 mg/dL (baseline 1.2 mg/dL)
Serum tacrolimus trough level: 24 ng/mL (target: 5-8 ng/mL)

Renal ultrasound reveals a normal-appearing allograft with no hydronephrosis and normal resistive indices.

Which of the following is the most appropriate next step in the management of this patient?

  1. A
    Decrease the daily dose of mycophenolate mofetil
  2. B
    Perform a percutaneous renal allograft biopsy
  3. Discontinue diltiazem and initiate metoprololAnswer
  4. D
    Add lisinopril to the patient's medication regimen
  5. E
    Measure prothrombin time and activated partial thromboplastin time

Answer

The correct answer is to discontinue diltiazem and initiate metoprolol.
The correct approach involves recognizing the critical drug-drug interaction between diltiazem and tacrolimus. Tacrolimus is a calcineurin inhibitor metabolized by the cytochrome P450 3A4 (CYP3A4) system. Diltiazem is a non-dihydropyridine calcium channel blocker and a potent inhibitor of CYP3A4. Initiation of diltiazem in a patient stabilized on tacrolimus leads to decreased tacrolimus clearance and toxic serum levels. Tacrolimus toxicity classically presents with acute kidney injury (due to afferent arteriolar vasoconstriction) and neurotoxicity (tremor, headache). The most appropriate next step is to discontinue the offending CYP3A4 inhibitor (diltiazem) and substitute it with a rate-control agent that does not significantly interact with CYP3A4, such as the beta-blocker metoprolol. Tacrolimus should also be temporarily withheld until levels return to the therapeutic range.

Step-by-Step Solution

1
Identify the primary clinical problem and its etiology.
The patient presents with acute kidney injury, tremor, and headache in the setting of a markedly elevated serum tacrolimus level (24 ng/mL).
These findings are classic for acute calcineurin inhibitor toxicity, which requires immediate intervention to prevent permanent renal damage.
2
Analyze the patient's medication history to find the root cause of the toxicity.
The recent addition of diltiazem, a potent CYP3A4 inhibitor, decreased the metabolism of tacrolimus, leading to its rapid systemic accumulation.
Tacrolimus is heavily dependent on the hepatic and intestinal CYP3A4 enzyme system for clearance.
3
Determine the appropriate treatment modification.
The offending interacting agent (diltiazem) must be discontinued. For continued rate control of atrial fibrillation, a non-interacting alternative like metoprolol should be initiated.
Removing the CYP3A4 inhibitor allows tacrolimus metabolism to normalize, resolving the acute toxicity while maintaining necessary cardiac treatment.

Key Concept

The metabolism of calcineurin inhibitors (like tacrolimus) is strongly dependent on the CYP3A4 enzyme system; concurrent administration of CYP3A4 inhibitors (such as diltiazem) causes rapid drug accumulation leading to acute kidney injury and neurotoxicity.
Estimated Time:1m 30s
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic